Spin-off News

Here you find a selection of press releases from Max Planck Innovation spin-offs.

13.03.2018

Clinical Data Presentations at AAT in Alzheimer's Disease. More

13.03.2018

Alnylam Reports New Clinical Results from the APOLLO Phase 3 Study of Patisiran for treating Amyloidosis. More

12.03.2018

Project Group ProDetekt at Life Science Inkubator (LSI) Sachsen receives maximum patent protection in Europe for PRET-ELISA key technology. More

12.03.2018

MorphoSys Reports Updated Data from L-MIND Study of MOR208 plus Lenalidomide in Aggressive Lymphoma (r/r DLBCL). More

11.03.2018

hte and Instituto de Tecnología Química announce successful commercialization of Micro Downflow Unit for FCC Catalyst Testing. More

11.03.2018

Alnylam Retains Global Rights to Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1). More

07.03.2018

Alacris among last 10 competitors for Cancer Research UK’s Grand Challenge award as a partner in an international research team. More

07.03.2018

Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform. More

21.02.2018

hte and SINOPEC RIPP intensify their collaboration. More

19.02.2018

MorphoSys Announces That Tremfya(R) (Guselkumab) Data Demonstrated Long-Term Skin Clearance In Patients With Moderate-To-Severe Plaque Psoriasis. More

16.02.2018

MorphoSys and Galapagos Present Results from a Phase 1 Study with MOR106 in Atopic Dermatitis. More

14.02.2018

Evotec and MaRS Innovation announce first funded project under LAB150 BRIDGE. More

01.02.2018

Protagen AG joins forces with the U.S. National Cancer Institute to answer pressing questions in immuno-oncology. More

31.01.2018

Life Science Inkubator (LSI) Bonn for the first time supports pharma industry spin-out. More

31.01.2018

Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis. More

29.01.2018

PreSens Precision Sensing: Facilitate calibrating of CO2 sensor foils. More

16.01.2018

The German National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG Investigate Responsiveness to Checkpoint Inhibitors in Melanoma. More

11.01.2018

OMV qualified hte to differentiate competitive catalysts for light cut naphtha isomerization. More

07.01.2018

Evotec and APEIRON achieve first milestone in immuno-oncology alliance with Sanofi. More

06.01.2018

Alnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance. More

31.12.2017

Innovativster Bioreaktor-Hersteller 2018 - bbi-biotech gewinnt Biotechnology Awards 2018. More

18.12.2017

Epigenomics AG gets CE-IVD Mark for Lung Cancer Test Epi proLung®. More

30.11.2017

Evotec receives clinical milestone as part of its discovery alliance with Boehringer Ingelheim. More

29.11.2017

MorphoSys Signs Regional License Agreement for Antibody MOR202 with I-Mab. More

22.11.2017

MorphoSys Announces That Its Licensee Janssen Has Received Approval for Tremfya(R) (Guselkumab) in Europe for the Treatment of Moderate-to-Severe Plaque Psoriasis. More

19.11.2017

U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy. More

06.11.2017

Alnylam Initiates ENVISION Phase 3 Clinical Study with Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs). More

05.11.2017

Evotec joins forces with academic leaders to accelerate drug discovery in kidney diseases and build "NEPLEX". More

25.10.2017

Evotec and Tesaro enter strategic partnership to discover novel immuno-oncology agents. More

22.10.2017

MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody MOR208 in Relapsed/Refractory DLBCL. More

17.10.2017

Alnylam and Vir Form Strategic Alliance to Advance RNAi Therapeutics for Infectious Diseases. More

10.10.2017

Proteros Joint Venture Rodin closes $27 million financing. More

09.10.2017

Evotec achieves first milestone in neurodegeneration alliance with Celgene. More

27.09.2017

European Investment Bank supports Evotec´s Innovate strategy with € 75 m loan. More

26.09.2017

MorphoSys and Galapagos Report First Promising Signs of Clinical Activity in a Phase 1 Study With IL-17C-Antibody MOR106 in Atopic Dermatitis Patients. More

25.09.2017

Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS). More

20.09.2017

MorphoSys Announces That Its Licensee Janssen Has Initiated Two Phase 3 Studies with TremfyaTM (Guselkumab) in Psoriatic Arthritis. More

19.09.2017

Epigenomics AG issues new shares by way of private placement. More

19.09.2017

Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy. More

18.09.2017

LSI project VesselSens is nominated as finalist for BioRiver Boost! More

12.09.2017

Lipid analysis for early stages of drug discovery Customer Reference Flagship VentureLabs. More

27.08.2017

New, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials. More

02.08.2017

LSI Project team SmartNanotubes receives 2m Euro fund from state for incubation. More

21.06.2017

Evotec´s LAB282 program for identifying and developing new approaches to treating serious diseases accelerates with second round funding. More

15.06.2017

Thermosome’s collaboration partner Philips publishes pre-clinical data of MR-HIFU mediated TSL-based drug delivery in PNAS. More

15.06.2017

Evotec receives European Mediscience Award for 'Company of the Year'. More

11.06.2017

Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office. More

10.06.2017

Probiodrug announces encouraging results of the Phase 2a SAPHIR Study for treating Alzheimer´s disease. More

04.06.2017

MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma. More

04.06.2017

MorphoSys Presents First Safety and Efficacy Data of MOR208 in Combination with Lenalidomide from a Phase 2 Study in DLBCL. More

01.06.2017

MorphoSys Starts Phase 3 Trial of MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL. More

31.05.2017

Body Labs Launches SOMA, the first ‘Human-Aware’ AI Platform for Predicting 3D Human Shape and Motion from Photos or Video. More

30.05.2017

FDA Grants Breakthrough Therapy Designation for Alnylam's Givosiran for the Prophylaxis of Attacks in Patients with Acute Hepatic Porphyria. More

21.05.2017

SCIENION and the COLODOR consortium announce the development of sensors for the detection of toxic volatile organic compounds in modern cooking equipment. More

21.05.2017

Evotec receives pre-clinical milestone as part of its Endometriosis Alliance with Bayer. More

18.05.2017

MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers. More

12.04.2017

Ribocon is involved in Aquavalens project seeking for improved molecular methods for the detection of pathogens in drinking water and water used in food preparation. More

10.04.2017

Life Science Inkubator: Study on treating tumor pain. More

10.04.2017

LDC and SOTIO Enter License and Collaboration Agreement for First-in-class Cancer Metabolism Program. More

06.04.2017

Lipotype´s Lipidomics as part of the IMI2 project RHAPSODY. More

05.04.2017

TOPTICA Photonics and Menlo Systems sign license agreement for optical frequency combs. More

04.04.2017

Evotec achieves first milestone in Diabetes alliance with Sanofi. More

27.03.2017

The measurement of light: Report in VDI News about Menlo System´s frequency combs. More

27.03.2017

hte qualified for independent testing of naphtha catalytic reforming application by Axens. More

19.03.2017

Arix Bioscience has signed an agreement with the Lead Discovery Center and the University of Leeds to develop new therapeutics for metabolic diseases. More

19.03.2017

Eupheria Biotech: New article in Small Methods 2017 about purified Cas9 fusion proteins. More

16.03.2017

The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran. More

08.03.2017

Largest skin lipidomics study provides a basis for personalized cosmetics and uses Lipotype technology. More

05.03.2017

MorphoSys Partner to Start New Phase 3 Clinical Trials with Gantenerumab in Alzheimer's Disease. More

02.03.2017

Epigenomics AG: U.S. Department of Veterans Affairs awards supply contract for Epi proColon®. More

28.02.2017

Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Givosiran for the Treatment of Acute Hepatic Porphyrias. More

13.02.2017

Venneos is featured in Laborjournal 1/2017. More

01.02.2017

Protagen AG join forces with the U.S. National Cancer Institute to answer pressing questions in immuno-oncology. More

29.01.2017

Epigenomics AG: Systematic study review supports use of Epi proColon® in blood-based cancer detection. More

18.01.2017

Evotec enters into an integrated drug discovery collaboration with Asahi Kasei Pharma (Japan). More

16.01.2017

The German National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG Investigate Responsiveness to Checkpoint Inhibitors in Melanoma. More

11.01.2017

MorphoSys Partner to Start Phase 2 Trial with Bimagrumab in Obese Patients with Type 2 Diabetes. More

09.01.2017

PreSens Precision Sensing GmbH: For 20 Years Precision Sensing around the World. More

08.12.2016

Evotec and Forge Therapeutics form strategic alliance to advance its novel Gram-negative antibiotic programme targeting 'LpxC' for the treatment of bacterial infections including those caused by drug resistant 'superbugs'. More

07.12.2016

The new navigation and mobility project moveBW, of which IONgate is a partner, is presented. More

05.12.2016

MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 2016 Conference. More

05.12.2016

MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016. More

04.12.2016

Alnylam Presents Updated Results from Phase 1/2 Study of ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). More

03.12.2016

Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors. More

02.12.2016

Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias. More

01.12.2016

SCIENION´s subsidiary Cellenion did make the next round in the BigBooster competition in France. More

29.11.2016

Evotec and Merck enter into agreements to collaborate on target discovery technologies. More

21.11.2016

Proteros signs second oncology collaboration with MSD on epigenetic target. More

20.11.2016

Nadicom: rhizo power® listed in FiBL organic input list for organic agriculture 2017. More

16.11.2016

SCIENION presents new sciREADER FL2 - high quality digital imaging of fluorescent assays with up to three colors. More

15.11.2016

Menlo Systems hosted the first Optical Frequency Comb User Conference. More

14.11.2016

MorphoSys Raises EUR 115 million in Private Placement. More

14.11.2016

MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in Psoriatic Arthritis. More

13.11.2016

Alnylam Pharmaceuticals Announces Sanofi Genzyme Opt-in Decision for Co-Development and Co-Commercialization of Fitusiran in Hemophilia and Rare Bleeding Disorders. More

12.11.2016

Alnylam Pharmaceuticals and The Medicines Company Announce Publication of Phase 1 Clinical Data with Inclisiran (ALN- PCSsc) in the New England Journal of Medicine. More

09.11.2016

Evotec and Oxford create novel Partnership called „LAB282“ to select and accelerate early-stage projects out of Oxford University with £ 13 m translational discovery fund. More

07.11.2016

ARUP Laboratories to Offer Epi proColon®, Epigenomics’ Blood-Based Colorectal Cancer Screening Test. More

01.11.2016

MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatology. More

24.10.2016

Cooling box from the Life Science Inkubator wins Saxon state prize for Design. More

28.09.2016

Evotec receives further important pre-clinical milestone in endometriosis alliance with Bayer. More

25.09.2016

Product release of MenloSystem´s TeraSmart, a 19”, 3U, all fiber-based Terahertz Time-Domain Spectrometer (THz-TDS). More

23.09.2016

Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1. More

20.09.2016

Evotec and Bayer partner to develop new treatments to fight kidney diseases. More

19.09.2016

neaspec: First infrared nano-spectroscopy demo at the Canadian synchrotron (CLS). More

11.09.2016

Market launch of nadicom´s Bio-fertilizer rhizo power® in Ireland. More

06.09.2016

Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AS1, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias. More

05.09.2016

Life Science Inkubator: The pain is gone - new therapy makes patients forget knee pain caused by gonarthrosis and meniscus injury. More

10.08.2016

Protagen Inks License Agreement with Inova Diagnostics for its proprietary BICD2 Biomarker. More

27.07.2016

SCIENION and Applied Microarrays announce a strategic partnership to deliver next generation medical devices. More

27.07.2016

New Network „UseCO2“: bbi biotech contributes Know-How within a cooperative founding project. More

24.07.2016

Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Rare Bleeding Disorders. More

28.06.2016

Investment company Ellersbrook will invest into Evotec's internal TargetNASH programme for the treatment of non-alcoholic steatohepatitis (NASH). More

16.06.2016

MorphoSys Reports Publication of Clinical Case Report of a Blood Cancer (DLBCL) Patient Showing Long-Lasting Complete Remission of Currently 26 Months under MOR208 Treatment. More

15.06.2016

Epigenomics’ Epi proColon® Included in Newly Issued USPSTF Guidelines for Colorectal Cancer Screening. More

14.06.2016

Protagen announces CE Mark for its proprietary Multilisa® BICD2 test for better diagnosis of Systemic Sclerosis. More

10.06.2016

Alnylam Reports Initial ALN-CC5 Results in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) from Ongoing Phase 1/2 Study. More

08.06.2016

Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis. More

06.06.2016

LDC Teams up with Canadian McGill University in $1 Million Translational Drug Discovery Project. More

23.05.2016

MorphoSys and MD Anderson Cancer Center Join Forces for the Development of Novel Oncology Therapeutics. More

23.05.2016

SCIENION inks Joint Development and Marketing pact with AXELA. More

23.05.2016

Evotec extends integrated drug discovery alliance with Genentech. More

08.05.2016

Start-up at Life Science Inkubator GmbH receives 1,39 million funding. More

08.05.2016

LabCorp is First U.S. Laboratory Network to Offer Epigenomics’ Epi pro Colon® Colorectal Cancer Screening Test, Nationally Available Immediately. More

03.05.2016

New tool from SCIENION and UCSD allows scientists to visualize nanoscale processes. More

28.04.2016

New platform for predictive modelling of cancer signalling: European Consortium around ALACRIS Theranostics GmbH “CanPathPro” started. More

25.04.2016

Evotec and ex scientia announce partnership to discover bispecific small molecule immuno-oncology therapeutics. More

24.04.2016

highQ among winners of award for digitally based mobility. More

19.04.2016

Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). More

05.04.2016

Thermosome raises €4.6m with first financing round and a research grant from the German government. More

03.04.2016

Probiodrug announces results of chronic toxicology studies with PQ912, its ‘first in class’ Glutaminyl Cyclase (QC) inhibitor for the treatment of Alzheimer’s disease. More

29.03.2016

Epigenomics enters strategic license and development agreement with BioChain on novel, blood-based lung cancer test. More

23.03.2016

Protagen AG have been nominated as one of three finalists in the 'Best Personalized Medicine Advance or Application' category of the prestigious Clinical and Research Excellence (CARE) awards. More

21.03.2016

Evotec spins off auto-immune disease company as 'Topas Therapeutics GmbH'. More

17.03.2016

Zealand & BioSolveIT create new therapeutic peptide drug design and development tool. More

13.03.2016

Alnylam Initiates Fitusiran (ALN-AT3) Dosing in Hemophilia A and B Patients with Inhibitors in Ongoing Phase 1 Study. More

09.03.2016

Evotec achieves milestone in collaboration with Padlock Therapeutics. More

08.03.2016

Alnylam Initiates Phase 1/2 Clinical Trial for ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1). More

29.02.2016

MenloSystems Product Release of SmartComb - a new era in Optical Frequency Combs. More

17.02.2016

hte supports Saudi Aramco in establishing a state-of-the-art high throughput experimentation facility in Dhahran, Saudi Arabia. More

10.02.2016

Novel route to serum based Prostate Cancer Diagnostics. More

01.02.2016

Evotec awarded grant from The Michael J. Fox Foundation for Parkinson's Research. More

31.01.2016

Alnylam Completes Enrollment in Phase 3 Study with Patisiran for Patients with Transthyretin (TTR)-Mediated Amyloidosis. More

25.01.2016

MorphoSys Announces Clinical Milestone for Start of Bayer's Phase 2 Trial Designed to Support Registration of Anetumab Ravtansine. More

06.01.2016

Proteros Joint Venture Rodin signs financing, research and option agreement with Biogen and Atlas Venture. More

09.12.2015

Evotec receives important pre-clinical milestones as part of its multi-target alliance with Bayer HealthCare. More

06.12.2015

Alnylam Reports Positive Phase 1 Study Results for Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) in Patients with Hemophilia A and B. More

08.11.2015

Epigenomics AG: Novel panel of blood-based DNA methylation biomarkers shows promising results in the detection of lung cancer. More

02.11.2015

Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension (OLE) Studies for Patisiran and Revusiran, in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis). More

06.10.2015

Lipotype GmbH and Nestlé Institute of Health Sciences collaborate on lipidomics research. More

30.09.2015

Alnylam and Genzyme Announce that Genzyme Opts into ALN-AT3 Hemophilia Program for Development and Commercialization Outside of North America and Western Europe. More

28.09.2015

LDC and Infinity Pharmaceuticals to Cooperate on the Identification of Novel Drug Discovery and Development Opportunities in Oncology. More

27.09.2015

Alnylam Granted Summary Judgment by United States District Court for the District of Massachusetts in Tuschl II Patent Inventorship Dispute. More

14.09.2015

Alnylam Reports Positive Initial Clinical Results for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias. More

08.09.2015

Evotec enters into licence and collaboration agreement with Pfizer Inc. in tissue fibrosis. More

24.08.2015

MorphoSys and Immatics Biotechnologies Enter Strategic Alliance in Immuno-oncology. More

09.08.2015

Evotec, Apeiron Biologics and Sanofi jointly develop novel small molecule-based cancer immunotherapies. More

28.07.2015

Alacris Theranostics GmbH: Basis for new treatment options for a fatal leukemia in children revealed. More

22.07.2015

MorphoSys Announces Clinical Milestone in Blood Disorders Program. More

29.06.2015

Evotec's partner Roche provides initial update from Phase IIb trial in Alzheimer's disease. More

22.06.2015

Alnylam Reports New Positive Clinical Data for ALN-AT3, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders. More

21.06.2015

SCIENION introduces a paradigm shift in Transmission Electron Microscopy by launching a new instrument, named sciTEM, enabling high-throughput and innovative SEM/TEM. More

16.06.2015

Intelligent Imaging Solutions releases new version of piccure+, a new application capable of correcting optical aberrations and camera shake that cause a lack of sharpness in photo images. More

10.06.2015

LDC to Collaborate with Johnson & Johnson Innovation on Acceleration of Academic Drug Discovery Initiatives. More

09.06.2015

neaspec GmbH and Fraunhofer IPM have developed a Terahertz near-field microscope at 30nm spatial resolution. More

31.05.2015

MenloSystems HARPS laser frequency comb is now installed on the HARPS planet-finding instrument on the ESO 3.6-metre telescope at the La Silla Observatory. More

31.05.2015

Lumics introduces next generation LuOcean Mini 4 high power fiber coupled diode laser module. More

31.05.2015

MorphoSys Presents Updated Phase 2 Clinical Results for MOR208 Monotherapy in NHL. More

30.05.2015

MorphoSys Presents First Safety, Pharmacokinetic and Efficacy Data for MOR202 in Multiple Myeloma at ASCO Meeting. More

25.05.2015

Alnylam Initiates Phase 1 Clinical Trial for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias, Including Acute Intermittent Porphyria (AIP). More

17.05.2015

Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration. More

28.04.2015

Facio partners with Evotec and initiates FSHD drug discovery programme. More

28.04.2015

Epigenomics receives EUR 2.8m grant for Validation of Lung Cancer Biomarkers in Blood Plasma. More

27.04.2015

NavigAID SLE - Protagen zooms into the micro cosmos of Autoimmune Disease. More

26.04.2015

Alacris wins the Deutsche Innovationspreis 2015. More

19.04.2015

The Charcot-Marie-Tooth Association Enters Collaboration with Affectis to Advance Therapies for Charcot-Marie-Tooth 1A Disorder. More

30.03.2015

Direvo Announces the USPTO Issuance of a Patent Claiming the Use of Enzyme Mixes In Biorefineries. More

30.03.2015

LDC and HZI enter partnership for the discovery of new drugs against multi-resistant bacteria. More

25.03.2015

MorphoSys and Celgene Mutually Agree to End MOR202 Collaboration. More

25.03.2015

Asahi Kasei Pharma selects Evotec as its partner for ion channel drug discovery. More

19.03.2015

Evotec and Sanofi sign definitive agreement for major multi-component strategic alliance amounting 250 mio. EUR. More

16.03.2015

Collaboration with the LDC to explore the development of a Englerin-A inspired cancer drug. More

14.03.2015

Alnylam Presents Results from Phase 2 Clinical Trial for Revusiran, an Investigational RNAi Therapeutic for the Treatment of FAC. More

08.03.2015

MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer. More

28.02.2015

Lumics adds new 760nm wavelength and reduces linewidth of its single-mode diode laser modules for analytic, sensing & seeding. More

01.02.2015

Alnylam Initiates Phase 1/2 Clinical Trial for ALN-CC5, an RNAi Therapeutic for the Treatment of Complement-Mediated Diseases. More

07.01.2015

Proteros enters into a collaboration with Bayer to develop new cardiovascular drug compounds for an integral membrane protein. More

31.12.2014

MenloSystems: BlueCut femtosecond micro-Joule laser - Faster and more efficient micro-material processing. More

News alert

Do you want to receive our newsletter and press releases?
Subscribe here

Media contact

Markus Berninger
Phone: (089) 290919-30